"Science Business" provides a fascinating history of pharmaceuticals and biotechnology. -- The Wall Street Journal, January 3, 2007
From the Back Cover
- Henri Termeer, Chairman, President and CEO, Genzyme Corporation
“In this startling and cogent diagnosis of, and prognosis for, the biotechnology industry, Gary Pisano weaves a powerful economic argument that all is not well in biotechnology, an industry that should be the best hope for a better healthcare for us all. We in the industry need better to grapple with the challenges posed by this provocative book."
- Dr. Josh Boger, President and CEO of Vertex Pharmaceuticals
“The industrial structure that has arisen in the United States to develop and exploit the potential of biotechnology is widely regarded as extremely effective. But is it? Few biotech firms have made a profit, and the rate of introduction of new effective pharmaceuticals is not impressive. Gary Pisano’s fine study is the first to bring these ideas into the open, analyze them, and reflect on what they might mean for the future of biotechnology.”
- Richard Nelson, George Blumenthal Professor of International and Public Affairs, Business and Law, Emeritus, Columbia University
“Gary Pisano's analysis uncovers surprising facts about the industry's innovation power and productivity, challenging conventional wisdom. Science Business is refreshing and inspiring for anyone who is interested in the future success of biotechnology, including life science executives, investors, policy-makers and, most importantly, the patients who it has the potential to help the most"
- Dr. Daniel Vasella, Chairman & CEO, Novartis AG